Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone versus eplerenone in worsening chronic heart failure with reduced ejection fraction
NL-OMON44143Phase 3Withdrawn
- Sponsor
- Bayer
- Start
- Sep 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic heart failure (CHF) and heart failure with reduced ejection fraction (HFrEF) comparing Finerenone arm with Eplerenone arm (2 arms). Primary endpoint: Time to first occurrence of cardiovascular death or hospitalization for heart failure. Planned start Sep 2015; status: withdrawn.
02
Drugs
finerenoneeplerenone
03
Conditions
chronic heart failure (CHF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON44143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44143.